Melanoma clonal heterogeneity leads to secondary resistance after adoptive cell therapy with tumor-infiltrating lymphocytes.
König D, Sandholzer M, Uzun S, Zingg A, Ritschard R, Thut H, Glatz K, Kappos EA, Schaefer DJ, Kettelhack C, Passweg JR, Holbro A, Baur K, Medinger M, Buser A, Lardinois D, Jeker LT, Khanna N, Stenner F, Kasenda B, Homicsko K, Matter M, Rodrigues Mantuano N, Zippelius A, Läubli H.
König D, et al. Among authors: buser a.
Cancer Immunol Res. 2024 Apr 17. doi: 10.1158/2326-6066.CIR-23-0757. Online ahead of print.
Cancer Immunol Res. 2024.
PMID: 38631025